Sei Naito
内藤诚二
MD, PhD
Professor of Urology; Director, Department of Urology泌尿外科学教授；泌尿外科主任
👥Biography 个人简介
Sei Naito, MD, PhD is a prominent Japanese urological oncologist who has led multicenter clinical studies of targeted therapies and immunotherapy combinations in renal cell carcinoma within the Japanese cooperative oncology groups. He has contributed extensively to understanding of non-clear cell RCC histologies, particularly papillary and chromophobe RCC, and has been instrumental in bringing new systemic therapies to patients in Japan through registration trials.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Japanese Multicenter RCC Clinical Trials
Led and co-led Japan Clinical Oncology Group (JCOG) and Kyushu University consortium trials evaluating sunitinib, axitinib, and nivolumab in Japanese metastatic RCC patients, documenting ethnicity-specific safety profiles and dosing adjustments.
Non-Clear Cell RCC Pathology and Treatment in Japan
Conducted one of Asia's largest series of papillary and chromophobe RCC outcomes, establishing baseline survival data and treatment response rates for non-clear cell histologies in the Japanese patient population.
Laparoscopic and Robotic Partial Nephrectomy for RCC
Pioneered minimally invasive nephron-sparing surgery for small renal masses at Kyushu University, contributing long-term oncological and functional outcomes data that informed Japanese urological society guidelines.
Biomarkers for VEGFR TKI Response in Japanese RCC
Investigated VEGFR and VHL mutation status as predictors of sunitinib and axitinib response in Japanese RCC cohorts, contributing to understanding of whether Western biomarker data translate to East Asian populations.
Representative Works 代表性著作
Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma
Japanese Journal of Clinical Oncology (2010)
Pivotal Japanese registration study establishing safety and efficacy of sunitinib in Japanese metastatic RCC patients, including documentation of ethnic-specific adverse event profiles.
Axitinib versus Sorafenib as Second-Line Treatment for Advanced Renal Cell Carcinoma in Asian Patients
Cancer Science (2015)
Subgroup analysis from AXIS trial confirming superiority of axitinib over sorafenib in the second-line setting among Asian patients with metastatic RCC.
Clinical Outcomes of Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Japanese Series
International Journal of Urology (2018)
Large multicenter Japanese analysis characterizing clinicopathological features, treatment patterns, and survival outcomes in papillary, chromophobe, and other non-ccRCC histologies.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 内藤诚二 的研究动态
Follow Sei Naito's research updates
留下邮箱，当我们发布与 Sei Naito（Kyushu University / Harasanshin Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment